Biotechnology

Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package

April 20, 2023 6:00 AM

- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies- - Dermata also submitted an end of phase 2 meeting package to the FDA - SAN DIEGO, CA / ACCESSWIRE / April 20, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it has received a...

Read more

BioInvent Announces a Fourth Complete Response in Phase 1/2 Trial with BI-1206 in Non-Hodgkin’s Lymphoma

April 20, 2023 2:20 AM

Reinforcing previous results and adding up to a total of four complete responses in the intravenous (IV) arm of the study Recruitment continues in the subcutaneous (SC) arm of the study; first data to be reported H1 2023 New patent granted in Japan relating to treatment of relapsed/refractory tumors LUND, SE / ACCESSWIRE / April 20, 2023 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the...

Read more

Form Bio Joins PacBio Compatible Program to Accelerate Gene Therapy Research From Data to Insights

April 19, 2023 9:00 AM

Combination of PacBio's HiFi Sequencing Capabilities and Form Bio's Computational Platform and Solutions Helps Biopharma and Academic Researchers Innovate and Accelerates Gene Therapy Product Development DALLAS, TX / ACCESSWIRE / April 19, 2023 / Form Bio, the provider of advanced computational life sciences technology, today announced it has joined the PacBio Compatible program. As part of the program, the Form Bio platform has been verified as...

Read more

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

April 18, 2023 1:30 PM

Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational status MINNEAPOLIS, MN / ACCESSWIRE / April 18, 2023 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies...

Read more

The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s (OTCPK:BWVI) Novel Topical Ketamine Delivery

April 18, 2023 9:00 AM

Psycheceutical Bioscience, Inc. Is Developing a Topical Application Of Ketamine Targeted to Relieve PTSD Symptoms Within Minutes and Negate Side Effects FT. LAUDERDALE, FL / ACCESSWIRE / April 18, 2023 / Psycheceutical Bioscience, Inc (OTC PINK:BWVI) is a biotechnology company developing a new and unique mode of administration that has the potential to completely revolutionize the psychedelic mental health space. With a staggering 52.9 million...

Read more

Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval

April 18, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. The review is required for approval to commence the next phase in the development of Pritumumab...

Read more

Brightstar Therapeutics Secures Series A Financing to Propel Groundbreaking Treatment for Corneal Diseases; Appoints Chief Medical Officer and Chief Scientific Officer to Lead

April 18, 2023 8:00 AM

LEXINGTON, KY / ACCESSWIRE / April 18, 2023 / Brightstar Therapeutics, a biotechnology company focused on providing innovative treatment options for corneal and ocular surface diseases, announced the closing of its Series A financing. The investment will fund the launch of its revolutionary approach to treating persistent epithelial defects and limbal stem cell deficiency with its advanced corneal allograft, BrightMEMTM. The allograft encourages...

Read more

Moolec Science Secures Up to $50 Million in Committed Equity Financing With Nomura

April 17, 2023 10:55 PM

LUXEMBOURG / ACCESSWIRE / April 17, 2023 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today it has entered into a Share Purchase Agreement ("Agreement") with Nomura Securities International, Inc. ("Nomura"). The Agreement provides for a committed equity financing facility under which the Company has the option,...

Read more

Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting

April 17, 2023 8:00 AM

BOSTON, MA / ACCESSWIRE / April 17, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the presentation of cinrebafusp alfa (PRS-343) clinical results from the Company's study in 2L+ HER2-positive gastric cancer at the American Association for Cancer...

Read more

HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

April 17, 2023 7:30 AM

HanchorBio Received IND Clearance of HCB101 Multi-regional Clinical Trial By US FDA TAIPEI, TAIWAN and SAN FRANCISCO, CA / ACCESSWIRE / April 17, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its...

Read more

Enzolytics, Inc. Announces Execution of Non-Binding Term Sheet with the Special Purpose Acquisition Company Sagaliam Acquisition Corp. and Updates the Progress on the African Project

April 17, 2023 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / April 17, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, and Sagaliam Acquisition Corp. (NASDAQ: SAGA) ("Sagaliam"), a special purpose acquisition company ("SPAC"), announced today, April 17, 2023, they have executed a non-binding term sheet for the sale of Biogenysis, Inc. ("BGEN") and Virogentics, Inc....

Read more

Monitchem Holdco 2 S.A.: Announces Launch of Offering of Floating Rate Notes due 2028 and Fixed Rate Notes Due 2028

April 17, 2023 4:00 AM

LONDON, UK / ACCESSWIRE / April 17, 2023 / Monitchem Holdco 3 S.A. (the " Issuer ") today announced that it has launched an offering of floating rate senior secured notes due 2028 (the " Floating Rate Notes ") and fixed rate senior secured notes due 2028 (the " Fixed Rate Notes " and, together with the Floating Rate Notes, the " Notes "), as part of the refinancing of the Issuer's existing floating rate senior secured notes due 2025 and fixed...

Read more

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

April 14, 2023 9:40 AM

NES-ZIONA, ISRAEL / ACCESSWIRE / April 14, 2023 / This month, H.C. Wainwright & Co. reiterated its buy rating for Enlivex Therapeutics Ltd. (NASDAQ:ENLV) with a 12-month price target of $15 per share, based on a valuation estimated at $320 million. Despite forecasting a net loss of $1.75 per share in 2023 largely due to high R&D spend, analysts believe the clinical-stage company's $50.2 million in cash and short-term deposits is enough to fund...

Read more

New Experimental Treatment for Prostate Cancer Revealed at AACR

April 14, 2023 8:00 AM

Evexomostat (SDX-7320) shows potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant. New research data to be presented at AACR 2023 in Orlando, FL ORLANDO, FL / ACCESSWIRE / April 14, 2023 / SynDevRx, Inc. today announced it will be presenting new anti-tumor data for its lead drug candidate evexomostat (SDX-7320) at the American Association for Cancer Research in Orlando, Florida on Monday, April 17...

Read more

New Nanocarrier Technology Promises Breakthrough in Delivery of Therapeutic Drugs Through Mucosal Membranes

April 14, 2023 8:00 AM

Research is currently underway to develop Cystic Fibrosis treatments OLATHE, KS / ACCESSWIRE / April 14, 2023 / Phoreus Biotech, a leading provider of next-generation peptide nanocarriers, has announced today a new addition to their portfolio of proprietary nanocarrier technologies. Amphipathic Peptide Capsules (APC) offer a new way to encapsulate nucleic acids and therapeutics in a water solution for improved delivery through mucosal membranes....

Read more

Biomed Industries, Inc. Offers to Buy Athenex, Inc.

April 13, 2023 10:55 AM

Offers $1.21 per share in cash Offer represents 100% premium to yesterday's closing price SAN JOSE CA / ACCESSWIRE / April 13, 2023 / Earlier today Biomed Industries, Inc., a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs, issued a letter to the Board of Directors of Athenex, Inc. The letter described a proposal to acquire all the company's common stock for $1.21 per share...

Read more

Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023 8:00 AM

MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to present at 1:30 p.m. ET on Wednesday, April 19, 2023. A live webcast of the...

Read more

Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Multiple Myeloma

April 11, 2023 9:00 AM

NEW YORK, NY / ACCESSWIRE / April 11, 2023 / Oncolyze, which already holds an Orphan Drug Designation for its lead drug candidate OM-301 in treating acute myeloid leukemia (AML), is pleased to announce that the FDA has just granted OM-301 its second Orphan Drug Designation, for multiple myeloma. Oncolyze Logo Oncolyze Logo There are approximately 35,000 cases of multiple myeloma yearly in the U.S. The five-year survival rate for multiple...

Read more

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

April 11, 2023 8:30 AM

- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development - Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma FRAMINGHAM, MA / ACCESSWIRE / April 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative...

Read more

Moolec Science Acquires Food Ingredient Capabilities to Consolidate Molecular Farming Technology

April 11, 2023 8:25 AM

LUXEMBOURG / ACCESSWIRE / April 11, 2023 / Moolec Science SA (NASDAQ:MLEC; "Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today the acquisition of plant-based food ingredient capabilities dedicated to the production and commercialization of functional soy proteins. This will help to accelerate Moolec's growth in the food ingredients industry by...

Read more